CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
20-297/S-007

Approval Letter
NDA 20-297/S-007

GlaxoSmithKline  
Attention: Ms. Catherine K. Clark  
1250 South Collegeville Road  
P.O. Box 5089  
Collegeville, PA  19426-0989

Dear Ms. Clark:

Please refer to your supplemental new drug application dated February 28, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Coreg (carvedilol) 3.125, 6.25, 12.5 and 25 mg Tablets.

We acknowledge receipt of your submission dated September 7 and 14, and October 3, 2001. Your submission of October 3, 2001 constituted a complete response to our August 31, 2001 action letter.

This supplemental new drug application provides for the use of Coreg (carvedilol) 3.125, 6.25, 12.5 and 25 mg Tablets for severe heart failure.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft labeling included in your October 3, 2001 submission.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-297/S-007." Approval of this submission by FDA is not required before the labeling is used.
All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are deferring the pediatric study requirement for this action for this application for pediatric patients ages one to sixteen years until October 3, 2004. We note that your pediatric studies are in progress.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Cardio-Renal Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions please call:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333

Sincerely,

(See appended electronic signature page)

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
20-297/S-007

Approvable Letter
NDA 20-297/S-007

GlaxoSmithKline
Attention: Ms. Catherine K. Clark
1250 South Collegeville Road
P.O. Box 5089
Collegeville, PA 19426-0989

Dear Ms. Clark:

Please refer to your supplemental new drug application dated February 28, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Coreg (carvedilol) 3.125, 6.25, 12.5 and 25 mg Tablets.

We acknowledge receipt of your submissions dated February 28 (patent information), and June 1 and 4, 2001.

This supplemental new drug application proposes for the use of Coreg (carvedilol) 3.125, 6.25, 12.5 and 25 mg Tablets for severe heart failure.

We note that your February 28, 2001 letter stated that your study of heart failure in pediatric patients is currently being evaluated under investigator sponsored IND [Robert Shaddy, M.D.] at the University of Utah.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to submit final printed labeling revised in accordance with the enclosed marked-up draft.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL, ten of which individually mounted on heavy weight paper or similar material.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.
In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Cardio-Renal Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Within 10 days after the date of this letter, you are required to amend the supplemental application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed. This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with these changes prior to approval of this supplemental application.

If you have any questions, please call:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333.

Sincerely,

[Signature]

(See appended electronic signature page)

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research
23 pages redacted from this section of the approval package consisted of draft labeling.